Hi Win
In the scheme of things this isn't too bad.
It is interesting to note that Merrill Lynch have decreased their estimate of PNV's 2H revenue by 10% to compensate for the effects of Omicron.
They also say that an appropriate EV/Revenue multiple of 17x is applicable for a global high-growth small cap medical technology company.
If this multiple was applied to ARX over time (once the company has proved itself) there will be a significant upward rerating of the share price.
Hi WinIn the scheme of things this isn't too bad. It is...
Add ARX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.5¢ |
Change
-0.010(1.80%) |
Mkt cap ! $189.3M | |||
| Open | High | Low | Value | Volume |
| 54.5¢ | 56.5¢ | 54.0¢ | $52.61K | 96.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 8736 | 54.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.0¢ | 1959 | 3 |
View Market Depth
| Last trade - 11.49am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
54.5¢ |
Change
-0.010 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 54.0¢ | 56.5¢ | 54.0¢ | 48141 | ||
| Last updated 12.14pm 30/05/2024 ? | |||||
| ARX (ASX) Chart |